<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929629</url>
  </required_header>
  <id_info>
    <org_study_id>D4930C00001</org_study_id>
    <nct_id>NCT01929629</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914</brief_title>
  <official_title>A Phase I, Randomized, Placebo-controlled, Single-center Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD0914 After a Single Oral Administration and to Assess the Effect of Food in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of orally administered
      AZD0914 in healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Randomized, Placebo-controlled, Single-center Study to Assess the Safety,
      Tolerability, and Pharmacokinetics of AZD0914 After a Single Oral Administration and to
      Assess the Effect of Food in Healthy Adult Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the safety profile in terms of adverse events; blood pressure, heart rate and body temperature; electrocardiograms; telemetry; clinical chemistry ; haematology and physical examination</measure>
    <time_frame>From admission on day -1 until follow up. ( Max 16 days)</time_frame>
    <description>Applies to Part A and B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics(PK) for AZD0914 study part A and B in terms of maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics(PK) for AZD0914 study part A and B in terms of time to reach maximum observed plasma concentration (tmax)</measure>
    <time_frame>Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics(PK) for AZD0914(Part A and B) in terms of AUC from time zero to time of last quantifiable AZD0914 concentration [AUC(0-last)]</measure>
    <time_frame>Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics(PK) for AZD0914(Part A and B) in terms of AUC from time zero to 24 hours after dosing [AUC(0-24)]</measure>
    <time_frame>Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics(PK) for AZD0914(Part A and B) in terms of terminal half-life (t1/2Î»z) and apparent plasma clearance (CL/F)</measure>
    <time_frame>Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics(PK) for AZD0914(Part A and B) in terms of apparent terminal phase volume of distribution (Vz/F), and at steady state (Vss/F),mean residence time</measure>
    <time_frame>Samples taken at predose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics(PK) for AZD0914 (Part A and B) in terms of cumulative amount of investigation product (IP) excreted unchanged into urine from zero to time t [Ae(0-t)],</measure>
    <time_frame>Samples taken from collections between -12 to 0 hours predose, and 0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 48, and 48 to 72 hours after the 1st dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics(PK) for AZD0914 (Part A and B) in terms of fraction of dose excreted unchanged into urine (fe), and renal clearance (CLr)</measure>
    <time_frame>Samples taken from collections between -12 to 0 hours predose, and 0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 48, and 48 to 72 hours after the 1st dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Gonococcal (GC) Infection</condition>
  <arm_group>
    <arm_group_label>Placebo fasting</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single or multiple dosing placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active fed condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD0914 given as single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A</intervention_name>
    <description>Single ascending doses</description>
    <arm_group_label>Placebo fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B</intervention_name>
    <description>Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.</description>
    <arm_group_label>Active fed condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female (of non-childbearing potential)subjects aged 18 to55 years
             (inclusive).

          -  Have a body mass index (BMI) between 18.00 and 30.50 kg/m2 and weigh at least 50 kg
             and no more than 100 kg

          -  Male subjects should be willing to use barrier contraception, ie, condoms, from the
             day of dose administration until at least 3 months after dose administration of the IP

        Exclusion Criteria:

          -  History of any important clinically significant disease or disorder which, in the
             opinion of the PI, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs

          -  Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks
             from the first administration of IP as judged by the PI

          -  History of gastrointestinal ulcer disease, inflammatory bowel disease, indigestion
             symptoms &gt;3 times a week, or blood in stool in previous 6 months not related to anal
             trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Phase I unit, Kansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Humphrey Gardener, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>First Time in Man</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

